2 results
Approved WMOWill not start
To evaluate the long-term safety and tolerability of elsubrutinib and upadacitinib given alone or as the ABBV-599 (elsubrutinib/upadacitinib) combination in SLE subjects who have completed the M19-130 Phase 2 study.
Approved WMOPending
Primary Objective: • To contrast Coherent Mapping quality (electrograms per map) and noise assessment using Octaray (with TRUEREF technology) versus Pentaray catheter for left and right atrium.Secondary Objective(s): • To contrast the Coherent…